The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.The phase 1/phase 2 trial did not meet its primary efficacy endpoint of objective response rate; however, the combination conferred a 12-month OS rate of 52.7% — which
Promising Results in Treatment for Recurrent Glioblastoma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
A new international study published in Nature Medicine and presented as a late-breaking abstract at the American Association of Neurological Surgeons annual conference, shows great promise for patients with glioblastoma.
Glioblastoma treatment shows promising results and can extend survival innovationtoronto.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from innovationtoronto.com Daily Mail and Mail on Sunday newspapers.